Category: pyrazoles-derivatives

In 2019 J ORG CHEM published article about N-HETEROCYCLIC CARBENE; ENANTIOSELECTIVE CONSTRUCTION; ORGANOCATALYSIS; PYRAZOLONES; ANNULATION; SCAFFOLDS; OXINDOLES; CATALYSIS in [Lu, Hong; Zhang, Huan-Xin; Tan, Chang-Yin; Liu, Jin-Yu; Xu, Peng-Fei] Lanzhou Univ, Sch Chem & Chem Engn, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China; [Lu, Hong; Wei, Hao] Northwest Univ, Coll Chem & Mat Sci, Natl Demonstrat Ctr Expt Chem Educ, Key Lab Synthet & Nat Funct Mol Chem,Minist Educ, Xian 710127, Shaanxi, Peoples R China in 2019, Cited 45. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0. Category: pyrazoles-derivatives

A sequential and general strategy has been successfully developed for the synthesis of spiropyrazolone scaffolds. This intriguing transformation of the asymmetric multicomponent catalysis process was realized with the combination of Michael addition/chlorination/nucleophilic substitution in a one-pot sequence, giving rise to a series of spiropyrazolones with fully substituted cyclopropanes and spiro-dihydrobenzofurans containing continuous stereogenic centers in good yields with excellent stereoselectivities.

Welcome to talk about 86-92-0, If you have any questions, you can contact Lu, H; Zhang, HX; Tan, CY; Liu, JY; Wei, H; Xu, PF or send Email.. Category: pyrazoles-derivatives

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Recently I am researching about POLYHALOGENATED NITROBUTADIENES; CHEMISTRY, Saw an article supported by the Belarusian Republican Foundation for Basic Research [X18M-023]. Published in MAIK NAUKA/INTERPERIODICA/SPRINGER in NEW YORK ,Authors: Kolesnyk, IA; Petkevich, SK; Tsaryk, AD; Kurman, PV; Potkin, VI. The CAS is 67-51-6. Through research, I have a further understanding and discovery of 3,5-Dimethyl-1H-pyrazole. Recommanded Product: 67-51-6

The reaction of 3,4,4-trichloro-1,1-bis(3,5-dimethyl-1H-pyrazol-1-yl)-2-nitrobuta-1,3-diene with 2-aminopyridine gave a polysubstituted pyrido[1,2-a]pyrimidine derivative with an aminopyridine residue in the 2-position, whereas heterocyclization of 3,4,4-trichloro-1,1-bis(1H-benzotriazol-1-yl)-2-nitrobuta-1,3-diene with substituted 2-aminopyridines afforded 2-(1H-berrzotriazol-1-yl)pyrido[1,2-a]pyrimidines. 2-(Morpholin-4-yl), 2-amino, and 2-(2-hydroxyethylamino) derivatives of polysubstituted pyrido[1,2-a]pyrimidines were synthesized, and those containing a 2-hydroxyethylamino group were converted to the corresponding 4,5-dichloro-1,2-thiazole-1-carboxylates. Specific features of heterocyclizations of benzotriazolyl and dimethylpyrazolyl derivatives of trichloronitro-1,3-butadiene to pyrimidine and pyrazole systems were revealed.

Recommanded Product: 67-51-6. Welcome to talk about 67-51-6, If you have any questions, you can contact Kolesnyk, IA; Petkevich, SK; Tsaryk, AD; Kurman, PV; Potkin, VI or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Recommanded Product: 3,5-Dimethyl-1H-pyrazole. I found the field of Chemistry; Science & Technology – Other Topics; Engineering very interesting. Saw the article Performance of Base and Noble Metals for Electrocatalytic Hydrogenation of Bio-Oil-Derived Oxygenated Compounds published in 2020.0, Reprint Addresses Gutierrez, OY; Holladay, JD (corresponding author), Pacific Northwest Natl Lab, Inst Integrated Catalysis, Energy & Environm Directorate, Richland, WA 99352 USA.. The CAS is 67-51-6. Through research, I have a further understanding and discovery of 3,5-Dimethyl-1H-pyrazole.

Electrocatalytic hydrogenation is a particularly attractive approach for converting the most unstable compounds in biogenic feedstocks at ambient conditions without external H-2. Here, we synthesized a variety of carbon-supported transition metal catalysts and characterized their activity for the electrocatalytic hydrogenation of a series of model compounds and pyrolysis bio-oil. Carbonyl compounds, especially aromatic aldehydes, such as furfural and benzaldehyde, are particularly inclined to hydrogenation driven by an applied current. This was verified with pure solutions of the model compounds and with pyrolysis bio-oil, where we achieved stable and steady continuous operation on Pd. When optimal catalyst composition was chosen, the conversion of benzaldehyde shifted from alcohol production (e.g., on Pd and Cu) to dimerization (e.g., on Co, Ni, and Zn). Pd and Cu were shown to offer the best compromise between reaction rates and efficiency although, in general, base metals offer similar conversions but better efficiencies than noble metals. Thus, the present work offers foundational results and guidelines for choosing the optimal metal catalyst and the applied potential for processing organic feedstocks as a function of its composition.

Recommanded Product: 3,5-Dimethyl-1H-pyrazole. Welcome to talk about 67-51-6, If you have any questions, you can contact Andrews, E; Lopez-Ruiz, JA; Egbert, JD; Koh, K; Sanyal, U; Song, M; Li, DS; Karkamkar, AJ; Derewinski, MA; Holladay, J; Gutierrez, OY; Holladay, JD or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

An article Synthesis of Polysubstituted Pyridopyrimidines, Pyrimidines, and Pyrazoles Based on 1,1-Bis(1H-benzotriazol-1-yl)-and 1,1-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-3,4,4-trichloro-2-nitrobuta-1,3-dienes WOS:000520467600004 published article about POLYHALOGENATED NITROBUTADIENES; CHEMISTRY in [Kolesnyk, I. A.; Petkevich, S. K.; Tsaryk, A. D.; Potkin, V. I.] Natl Acad Sci Belarus, Inst Phys Organ Chem, Minsk 220072, BELARUS; [Kurman, P. V.] Natl Acad Sci Belarus, Inst Bioorgan Chem, Minsk 220141, BELARUS in 2020.0, Cited 16.0. Quality Control of 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

The reaction of 3,4,4-trichloro-1,1-bis(3,5-dimethyl-1H-pyrazol-1-yl)-2-nitrobuta-1,3-diene with 2-aminopyridine gave a polysubstituted pyrido[1,2-a]pyrimidine derivative with an aminopyridine residue in the 2-position, whereas heterocyclization of 3,4,4-trichloro-1,1-bis(1H-benzotriazol-1-yl)-2-nitrobuta-1,3-diene with substituted 2-aminopyridines afforded 2-(1H-berrzotriazol-1-yl)pyrido[1,2-a]pyrimidines. 2-(Morpholin-4-yl), 2-amino, and 2-(2-hydroxyethylamino) derivatives of polysubstituted pyrido[1,2-a]pyrimidines were synthesized, and those containing a 2-hydroxyethylamino group were converted to the corresponding 4,5-dichloro-1,2-thiazole-1-carboxylates. Specific features of heterocyclizations of benzotriazolyl and dimethylpyrazolyl derivatives of trichloronitro-1,3-butadiene to pyrimidine and pyrazole systems were revealed.

Welcome to talk about 67-51-6, If you have any questions, you can contact Kolesnyk, IA; Petkevich, SK; Tsaryk, AD; Kurman, PV; Potkin, VI or send Email.. Quality Control of 3,5-Dimethyl-1H-pyrazole

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Quality Control of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Recently I am researching about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX, Saw an article supported by the BayerBayer AG; Amgen MerckAmgenMerck & Company; RocheRoche Holding. Published in DOVE MEDICAL PRESS LTD in ALBANY ,Authors: Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Welcome to talk about 83-10-3, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or send Email.. Quality Control of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Space Craft-like Octanuclear Co(II)-Silsesquioxane Nanocages: Synthesis, Structure, Magnetic Properties, Solution Behavior, and Catalytic Activity for Hydroboration of Ketones WOS:000463462200062 published article about COORDINATION POLYMERS; SELECTIVE HYDROBORATION; MASS-SPECTROMETRY; METAL; ALDEHYDES; COMPLEXES; CARBONYL; COBALT; CLUSTERS; HYDROGENATION in [Liu, Ya-Nan; Wang, Wen-Guang; Tung, Chen-Ho; Sun, Di] Shandong Univ, State Key Lab Crystal Mat, Sch Chem & Chem Engn, Key Lab Colloid & Interface Chem,Minist Educ, Jinan 250100, Peoples R China; [Li, Yun-Wu; Sun, Di] Liaocheng Univ, Shandong Prov Key Lab Chem Energy Storage & Novel, Liaocheng 252000, Shandong, Peoples R China; [Li, Yun-Wu; Sun, Di] Liaocheng Univ, Sch Chem & Chem Engn, Liaocheng 252000, Shandong, Peoples R China; [Su, Hai-Feng] Xiamen Univ, Coll Chem & Chem Engn, State Key Lab Phys Chem Solid Surfaces, Xiamen 361005, Peoples R China; [Su, Hai-Feng] Xiamen Univ, Coll Chem & Chem Engn, Dept Chem, Xiamen 361005, Peoples R China; [Jaglicic, Zvonko] Univ Ljubljana, Fac Civil & Geodet Engn, Jamova 2, Ljubljana 1000, Slovenia; [Jaglicic, Zvonko] Univ Ljubljana, Inst Math Phys & Mech, Jamova 2, Ljubljana 1000, Slovenia; [Liu, Qing-Yun] Shandong Univ Sci & Technol, Coll Chem & Environm Engn, Qingdao 266590, Shandong, Peoples R China in 2019.0, Cited 97.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6. Product Details of 67-51-6

Two novel space craft-like octanuclear Co(II)-silsesquioxane nanocages, {Co-8[(MeSiO2)(4)](2)(dmpz)(8)} (SD/Co8a) and {Co-8[(PhSiO2)(4)](2)(dmpz)(8)} (SD/Co8b) (SD = SunDi; Hdmpz = 3,5-dimethylpyrazole), have been constructed from two similar multidentate silsesquioxane ligands assisted with a pyrazole ligand. The Cob skeleton consists of eight tetrahedral Co(II) ions arranged in a ring and is further capped by two (MeSiO2)(4) ligands up and down. The auxiliary dmpz(-) ligands seal the ring finally. Electrospray ionization mass spectrometry revealed SD/Co8a and SD/Co8b are highly stable in CH2Cl2. Magnetic analysis implies that SD/Co8a announces antiferromagnetic interactions between Co(II) ions. Moreover, both of them display good homogeneous catalytic activity for hydroboration of ketones in the presence of pinacolborane under mild conditions.

Welcome to talk about 67-51-6, If you have any questions, you can contact Liu, YN; Su, HF; Li, YW; Liu, QY; Jaglicic, Z; Wang, WG; Tung, CH; Sun, D or send Email.. Product Details of 67-51-6

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

An article A real-time data-based scan conversion method for single element ultrasound transducers WOS:000464437300004 published article about DECORRELATION; SPECKLE; TISSUE in [Csany, Gergely; Gyongy, Miklos] Pazmany Peter Catholic Univ, Fac Informat Technol & Bion, Budapest, Hungary; [Szalai, Klara] Semmelweis Univ, Dept Dermatol Venerol & Dermatooncol, Budapest, Hungary in 2019, Cited 42. Recommanded Product: 83-10-3. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3

The current work investigates the performance of a real-time scan conversion algorithm for generating a 2-D ultrasound image from a laterally scanned single-element ultrasound transducer, which has applications in point-of-care devices such as for skin imaging. The algorithm employs a fixed calibration curve to update a predefined image grid in real time. Simulations showed that the calibration curve (with a maximum of 1) is robust to changes in scatterer concentration (8.3 x 10(-3) mean absolute error), signal to noise ratio (1.0 x 10(-3) mean absolute error for -5 dB SNR), and can be accurately predicted from a small number (31) of point scatterers (6.9 x 10(-3) mean absolute error). Good agreement was also found between the calibration curves obtained from simulated and experimental data (1.19 x 10(-2) mean absolute error). The scan conversion algorithm was validated by evaluation of the position estimation errors on both simulations and experiments. Clinical images of skin lesions (N = 20) demonstrate the feasibility of the algorithm for real, non-homogeneous tissue. Use of a fixed calibration curve compared to an adaptive calibration curve gave similar accuracies in the scanning step size range of 150-350 mu m (with an average overlap of the accuracy ranges of 92.94% for simulations and 42.83% for experiments), and a 350-fold improvement in computation time.

Recommanded Product: 83-10-3. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Name: 3-Methyl-1-p-tolyl-5-pyrazolone. In 2019 ACS OMEGA published article about C-H; BIOLOGICAL EVALUATION; PHOTOREDOX CATALYSIS; IN-VITRO; ALPHA-GLUCOSIDASE; PYRAZOLE; DERIVATIVES; POTENT; INHIBITORS; DESIGN in [Ibrahim, Hamada Mohamed; Behbehani, Haider] Kuwait Univ, Fac Sci, Chem Dept, POB 5969, Safat 13060, Kuwait; [Ibrahim, Hamada Mohamed] Fayoum Univ, Fac Sci, Chem Dept, POB 63514, Al Fayyum, Egypt in 2019, Cited 99. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

A novel, metal catalyst-free, and efficient method has been developed for the synthesis of (pyrazol-4-ylidene) pyridine derivatives. The process involves dehydrogenative coupling of 1-amino-2-imino-pyridines with 1-aryl-5pyrazolone derivatives utilizing O-2 as the sole oxidant. The new method benefits from a high atom economy, efficiency, and substrate scope, as well as the simplicity of reaction and product purification procedures.

Name: 3-Methyl-1-p-tolyl-5-pyrazolone. Welcome to talk about 86-92-0, If you have any questions, you can contact Ibrahim, HM; Behbehani, H or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Application In Synthesis of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. In 2020 CANCER MANAG RES published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.. Application In Synthesis of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. In 2020 CANCER MANAG RES published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics